Table 4.
Molecular characterization and outcomes of the 4 studies.
| Study | Characteristics | MMR-D | POLE-Mutated | p53abn | p53wt | P1 | Total |
|---|---|---|---|---|---|---|---|
| Summary of the 4 studies | Number | 23 (21.7) | 3 (2.8) | 3 (2.8) | 77 (72.6) | – | 106 |
| CR rate at 6 months | 11 (47.8) | 2 (2/3) | 2 (2/3) | 50 (64.9) | 0.152 | 64 (60.4) | |
| Best overall response of CR/PR rate | 14 (60.9) | 2 (2/3) | 2 (2/3) | 62 (80.5) | 0.092 | 80 (75.6) | |
| Recurrence rate after CR/Progression | 3 (13.0) | 1 (1/3) | 2 (2/3) | 23 (29.9) | 0.174 | 29 (27.4) | |
| Hysterectomy | 8 (34.8) | 2 (2/3) | 1 (1/3) | 32 (41.6) | 0.633 | 43 (40.6) |
1Patients with POLE-mutated (n = 3) or p53abn (n = 3) were excluded.